Financial Data and Key Metrics Changes - Revenue for the year increased by 82% to $6,000,000,000, driven by market share growth and the Sigma wholesale business [6][10] - Normalized EBIT rose by 41% to $835,000,000, with pro forma EBIT at $903,400,000 [6][11] - Normalized net profit after tax increased by 40% to $579,000,000, with a strong balance sheet showing net debt of $752,000,000 [6][12] - The company declared a final dividend of $0.13 per share, fully franked [7][22] Business Line Data and Key Metrics Changes - Chemist Warehouse retail network sales reached $10,000,000,000, up 14% for the year, with 35 new stores added [3][4] - Own brand portfolio grew by over 20% for the year, contributing to overall growth [4][31] - Combined distribution center volumes increased by 29% to over 530 million units, leading to a reduction in cost per unit by $0.11 [4][11] Market Data and Key Metrics Changes - The Chemist Warehouse Australian store network achieved 11.3% like-for-like sales growth [18] - International expansion included 16 new stores opened offshore, with a total of 77 stores across New Zealand, Ireland, and Dubai [29] - The company anticipates continued growth in international markets, particularly in New Zealand, where retail sales have exceeded $1,000,000,000 [29] Company Strategy and Development Direction - The company focuses on four key growth pillars: domestic growth, international expansion, product differentiation, and improved efficiencies [24][25] - Domestic growth aims to expand market leadership and pharmacy network in underpenetrated locations [26] - International expansion is seen as a growth engine, with a focus on profitable growth in existing markets [25][29] - The company has upgraded synergy targets from $60,000,000 to $100,000,000 per annum, expected to be achieved over the next four years [5][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute plans effectively, with positive momentum continuing into FY 2026 [36] - The operating environment remains competitive, particularly in the health and beauty space, but the company maintains a strong value proposition [69] - Management noted that the merger has strengthened the business, providing enhanced scale and long-term growth pathways [35] Other Important Information - The company has a conservative leverage ratio of 0.85x, indicating strong cash flows and funding capacity [12][21] - The merger accounting has resulted in an increase in goodwill by $3,600,000,000 [21] Q&A Session Summary Question: Profit contribution from Wagner's product line into 2026 - Management indicated that while there was a benefit in FY 2025, full-year benefits from Wagner's will be realized in 2026 as the product range expands [39] Question: Margin drivers for the future - Management stated that margin enhancement will come from a mix of product strategy, operational efficiencies, and growth in network scale [40] Question: Cost control and inflation outlook - Management confirmed that while some inflation is expected, the existing infrastructure allows for cost efficiencies without linear growth in costs [44][45] Question: Synergy target upgrade rationale - The upgrade to the synergy target was driven by detailed analysis post-merger, identifying multiple areas for improvement beyond just supply terms [49][50] Question: Addressing under-penetration in certain markets - Management explained that regulatory processes are in place to facilitate store openings in under-penetrated areas, with a history of successful approvals [53] Question: Expected D&A and CapEx for FY 2026 - Management expects D&A to remain consistent, with potential investments in international markets being evaluated [55][57] Question: Impact of establishing a distribution center in Ireland - Management believes that the new distribution center will positively impact profitability and support growth in the Irish market [62][64] Question: Competitive dynamics in health and beauty products - Management emphasized the company's competitive pricing and product range as key advantages over supermarkets [69] Question: Uptake of GLP-1 products - Management confirmed a material uptake in GLP-1 products, with expectations for continued growth [71] Question: Performance benchmarking in Ireland - Management indicated that turnover per store in Ireland compares favorably to New Zealand and Australia, suggesting strong growth potential [78]

Financial Data and Key Metrics Changes - Revenue for the year increased by 82% to $6,000,000,000, driven by market share growth and the Sigma wholesale business [6][10] - Normalized EBIT rose by 41% to $835,000,000, with pro forma EBIT at $903,400,000 [6][10] - Normalized net profit after tax increased by 40% to $579,000,000, with a strong balance sheet showing net debt of $752,000,000 [6][11] Business Line Data and Key Metrics Changes - Chemist Warehouse retail network sales reached $10,000,000,000, up 14% for the year, with 35 new stores added [3][4] - Own brand portfolio grew by over 20%, contributing significantly to the growth strategy [4][30] - Combined distribution center volumes increased by 29%, leading to a reduction in cost per unit by $0.11 [4][11] Market Data and Key Metrics Changes - The Chemist Warehouse Australian store network delivered 11.3% like-for-like sales growth [17] - International expansion included 16 new stores opened offshore, with a total of 77 stores across New Zealand, Ireland, and Dubai [28] - The company anticipates continued growth in the international markets, particularly in New Zealand [28][29] Company Strategy and Development Direction - The company focuses on four key growth pillars: domestic growth, international expansion, product differentiation, and improved efficiencies [23][24] - Domestic growth aims to expand market leadership and pharmacy network in underpenetrated locations [25] - International expansion is seen as an emerging growth engine, with a focus on profitable growth in existing markets [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute plans effectively, with positive momentum continuing into FY 2026 [34][35] - The merger is expected to provide significant synergies, with an upgraded target of $100,000,000 per annum [5][48] - Management noted that the health and beauty space remains competitive, but the company continues to gain market share [66] Other Important Information - The company declared a final dividend of $0.13 per share, fully franked, in line with its stated payout ratio [6][21] - The balance sheet remains strong, with a conservative leverage ratio of 0.85x [11][20] Q&A Session Summary Question: Discussion on Wagner's product profit increment into 2026 - Management indicated that while there was a benefit in 2025, full-year benefits from Wagner are expected in 2026 as the product range expands [37] Question: Margin drivers and synergy achievement - Management stated that margin enhancement will come from a mix of own label products, operating leverage, and growth [38] Question: Cost inflation and operating leverage - Management explained that operating leverage will be driven by existing capacity in distribution centers, with some inflation expected [44] Question: Synergy upgrade from $60 million to $100 million - The upgrade was driven by detailed data analysis post-merger, identifying multiple areas for synergy beyond just supply terms [48] Question: Addressing under-penetration in certain markets - Management noted that regulatory challenges exist, but they have successfully worked with regulators to gain approvals for new stores [52] Question: Expected D&A and CapEx for FY 2026 - Management expects D&A to remain consistent, with CapEx also expected to be stable unless compelling investment opportunities arise [56][57] Question: Impact of establishing a distribution center in Ireland - Management believes the new DC will positively impact profitability and support growth in the Irish market [60][62] Question: Competitive dynamics in health and beauty products - Management acknowledged competition but emphasized their competitive pricing and product range as advantages [66] Question: Uptake of GLP-1 products - Management confirmed a material uptake in GLP-1 products, expecting continued growth without a slowdown [68]

Core Insights - Taylor Devices, Inc. (TAYD) experienced a 4.7% stock increase following its earnings report for the quarter ended May 31, 2025, outperforming the S&P 500 index, which declined by 1.2% during the same period. However, the stock has seen a 5.8% decline over the past month, indicating potential company-specific concerns or broader market factors affecting performance [1] Quarterly Performance - In the fourth quarter of fiscal 2025, Taylor Devices reported earnings per share of $1.17, an increase from 80 cents in the prior-year quarter. Sales reached $15.6 million, reflecting a 29% rise from $12.1 million in the same quarter last year. Net earnings for the quarter were $3.7 million, compared to $2.5 million a year earlier, marking a 49% increase [2] Full-Year Performance - For the full fiscal year 2025, sales reached a record $46.3 million, up 4% from $44.6 million in fiscal 2024. Net income climbed to $9.4 million, a 5% improvement from $9 million the previous year. Full-year earnings per share rose to $3.01 from $2.68 [3] Business Metrics - Taylor Devices ended fiscal 2025 with a firm order backlog of $27.1 million, indicating continued customer demand and providing visibility into near-term revenues. All three customer-facing product groups—Aerospace/Defense, Structural, and Industrial—positively contributed to the results, with Aerospace/Defense and Industrial markets showing strong momentum [4] Management Commentary - CEO Tim Sopko highlighted that both the fourth quarter and the full fiscal year marked record highs for sales and profitability. The net income of $9.4 million represented 20.3% of sales, slightly higher than last year's 20.2% ratio, indicating steady margins despite macroeconomic challenges. Management attributed the performance to effective execution of growth strategies and ongoing investments in people, technology, processes, and facilities [5] Influencing Factors - The company's performance was bolstered by strong demand in Aerospace/Defense and Industrial sectors, which offset weaknesses in Structural markets. Elevated interest rates negatively impacted construction-related demand in structural products, while foreign exchange volatility posed additional challenges for international sales. Despite these issues, operating leverage from higher volumes and cost discipline supported both revenue and earnings growth [6]

Core Viewpoint - Microchip reported a strong start to fiscal year 2026 with a sequential revenue increase of 10.8%, reaching approximately $1.0755 billion, although it experienced a year-over-year decline of 13.4% [3][7]. Financial Performance - For Q1 FY26, net sales were $1.0755 billion, with a non-GAAP net profit of $154.7 million, translating to diluted earnings per share of $0.27, down from $289.9 million and $0.53 in the same quarter last year [3][4]. - The gross profit margin was 54.3%, while the operating income margin was 20.7% [9]. Strategic Initiatives - The CEO highlighted a significant inventory reduction of $124.4 million, with distribution inventory days decreasing by 4 days to 29 days, and total inventory days down to 214 days, enhancing operational efficiency [8]. - The CFO noted that the company’s business model demonstrated leverage, achieving a non-GAAP gross margin of 76% and an operating margin of 82% for new revenue [8]. Future Guidance - For Q2 FY26, the company expects net sales to be approximately $1.13 billion, representing a sequential growth of about 5.1% [8][11]. - The company plans to maintain a cautious approach due to the changing macro environment while believing in its ability to achieve sustained growth and enhance shareholder value throughout FY26 [8]. Capital Expenditure - Projected capital expenditures for Q2 FY26 are estimated between $35 million and $40 million, with total capital expenditures for FY26 expected to be $100 million or less [11].

Financial Data and Key Metrics Changes - RevPAR grew by 1.8%, reflecting the company's geographic footprint and brand depth [6] - Gross system growth was 7.7% and net system growth was 5.4%, driven by development activity and record openings [6] - EBIT increased by 13% and adjusted EPS grew by 19% [6] - The company completed 47% of its $900 million share buyback program, returning over $1.1 billion to shareholders this year [6] Business Line Data and Key Metrics Changes - The Americas fee revenues were down about 1% despite a 1.5% RevPAR growth and around 1.5% adjusted net unit growth [10] - The company signed over 51,000 rooms across 324 hotels, a 15% increase over 2024 [6][20] - Openings in The Americas were up 40% year over year, contributing to future fee growth [24] Market Data and Key Metrics Changes - The company reported a constructive outlook for US demand and hospitality performance, with stable inflation and interest rates [14][15] - In China, the company sees the economy bottoming out, with GDP growth of about 5% in Q2 and expectations for improved RevPAR trends in the back half of the year [66][68] Company Strategy and Development Direction - The company is focused on high-growth opportunities, including investments in technology and expanding its luxury and lifestyle brands [52][54] - The company aims to grow both new builds and conversions, with a strong pipeline of openings and signings [63][110] - The branded residential segment is expected to contribute consistently to fee growth, with 30 properties currently open and more in development [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year profit and EPS consensus, despite uncertainties in the short term [15][85] - The company noted that the fundamentals for US hospitality remain strong, with job growth and corporate capital investment driving demand [14][15] - Management is optimistic about the long-term growth potential in China, despite current challenges [66][68] Other Important Information - The company has been investing in technology and process improvements to enhance operational efficiency and scalability [94] - The company expects to see continued margin growth driven by cost savings and ancillary revenue streams [95] Q&A Session Summary Question: Current trading outlook for Q3 and Q4 RevPAR in the U.S. - Management does not provide guidance but feels comfortable with full-year profit and EPS consensus, indicating a stable outlook for U.S. demand [12][15] Question: Explanation for the decline in Americas fee revenues despite RevPAR growth - Management attributed the decline to high-fee hotels exiting and renovations impacting available rooms, but does not see it as a long-term issue [20][22] Question: Insights on branded residential contribution to profitability - Management is excited about the growth trajectory in branded residential, which is expected to contribute consistently to fees [31][33] Question: Investment focus among technology pillars - Management emphasized ongoing investments in technology, particularly in PMS and RMS systems, to ensure competitiveness [34][38] Question: Update on the performance of the Garner brand - Management reported strong progress with 51 open Garners and a robust pipeline, indicating significant international demand [78][79]

Core Viewpoint - Amazon's stock performance has lagged behind the market primarily due to the disparity between revenue growth and earnings per share (EPS) growth, with expected revenue growth of 9.4% and EPS growth of only 3.6% for Q2 [3][4]. Financial Performance - For the upcoming quarters, Amazon's EPS growth is projected to consistently lag behind revenue growth, indicating potential concerns about operational leverage and fundamental issues [4]. - Analysts remain optimistic, attributing the temporary slowdown in EPS growth to significant investments in growth and innovation rather than cost management issues [5]. - Amazon's R&D spending has exceeded $90 billion over the past 12 months, more than double that of fiscal year 2020, indicating a strong commitment to innovation [5]. Future Earnings Estimates - Analysts have revised future EPS estimates positively, with projections for fiscal years 2031-2033 seeing increases of over 20%, suggesting confidence in Amazon's long-term investment strategy [6]. - The expected P/E ratio for Amazon is projected to decline significantly over the next five years, reflecting a positive outlook on the company's market position in e-commerce and cloud services [10][11]. Earnings Surprise Record - Amazon has consistently exceeded Wall Street's EPS expectations over the past eight quarters, with only one instance of revenue falling short, indicating strong operational performance [7]. Market Valuation - The average target price set by Wall Street analysts for Amazon is relatively conservative at $247, suggesting limited short-term upside potential [8]. - The current TTM P/E ratio of 37.35 is considered low for Amazon, especially compared to historical levels during market downturns [15]. Long-term Investment Perspective - Amazon's strategy of increasing its robotics workforce is expected to yield significant long-term value for shareholders by reducing labor costs, with potential market cap increases of 13%-40% based on conservative estimates [12][13]. - For patient long-term investors, Amazon remains a strong buy due to its proactive innovation spending likely to yield returns over time [16].

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $17.2 million, representing a 71% increase year-over-year [9][24] - For fiscal year 2025, total revenue reached $59.8 million, a 115% increase compared to fiscal year 2024 [24] - Gross margin improved to 44.3% in Q4 2025 from 13.9% in the prior year [10][25] - Fiscal year 2025 gross margin was 40.5%, up from 1.3% in fiscal year 2024 [11][25] - GAAP net loss for Q4 2025 was $51.1 million, compared to a loss of $22.3 million in the prior year [29] - Adjusted EBITDA loss for Q4 2025 was $20.3 million, compared to a loss of $16.5 million in the prior year [29] Business Line Data and Key Metrics Changes - The Assure system generated over 3,900 prescriptions in Q4 2025, a 43% increase year-over-year [9] - Revenue growth was driven by a higher mix of in-network patients and improvements in revenue cycle management capabilities [24][25] Market Data and Key Metrics Changes - Covered lives for the Assure system now total over 285 million health plan members in the U.S. [13] - The company is targeting geographies with high volumes of WCD prescriptions and strong in-network payer coverage [12] Company Strategy and Development Direction - The company aims to expand its commercial team and enhance revenue cycle management capabilities [11][12] - Plans to nearly double sales coverage over the next few years, increasing from approximately 80 sales territories [12] - The company is focused on continuous innovation and has over 365 patent assets [14][15] - The goal is to make the Assure system the standard of care for patients at risk of sudden cardiac arrest [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant operating leverage and gross margin expansion over the next few years [11][30] - The company expects revenue of $85 million for fiscal year 2026, a 42% increase compared to fiscal year 2025 [30] - Management highlighted the underutilization of WCD therapy, indicating a significant market opportunity [16][17] Other Important Information - The company is not subject to competitive bidding due to the Assure system being a class III medical device [26] - The company is focused on building clinical evidence to support the safety and efficacy of the Assure system [15][84] Q&A Session Summary Question: Guidance for fiscal year 2026 and underlying assumptions - Management indicated that revenue growth will be driven by sales territory productivity, expansion plans, and penetration of existing accounts [33][35] Question: Margin expansion potential - Management noted that margin expansion is expected due to increasing volumes and improved revenue per fit [37][38] Question: Sole source contract with a provider network - Management explained that the contract allows for better patient management and smoother revenue cycle processes [40][42] Question: Seasonality considerations for fiscal year 2026 - Management stated that prescription growth is expected to average 40% per quarter, with higher conversion rates in the first half of the year [44][45] Question: Competitive response and guidance - Management clarified that the guidance reflects normal scaling and territory ramp-up, with no significant competitive issues [48][50] Question: Conversion rate drivers - Management identified fill rate, claim conversion, and in-network patient mix as key drivers of the conversion rate [59][61] Question: Plans for randomized trials - Management is focused on executing the post-approval study and leveraging the data from the registry [83][85]

Core Viewpoint - S.F. Holding is initiated with an OUTPERFORM rating and target prices of HK$50.37 for H-shares and Rmb51.87 for A-shares, driven by improving logistics network and domestic demand for logistics services [1] Investment Positives - The logistics market in Asia is the largest globally, accounting for 46% in 2023, with S.F. Holding ranking No.1 in various submarkets [1] - The company is expected to leverage its logistics network and diversified product portfolio to reduce logistics costs for clients [1] Operating Efficiency - The capex-to-revenue ratio has decreased from 13.9% in 2021 to 3.8% in 2024, indicating improved operating leverage and capacity utilization [2] - Earnings visibility has improved due to better control over investment pace [2] Revenue Growth Projections - Revenue for express and freight, global supply chain, and intra-city delivery segments is expected to grow at CAGRs of 9%, 3%, and 19% respectively from 2024 to 2026 [3] - Gross margin is projected to rise by an average of 0.4 percentage points per year [3] Market Differentiation - Historical fluctuations in business operations are attributed to mismatches between capacity investment and market demand cycles [4] - The company’s logistics network construction is expected to reduce cyclical fluctuations significantly [4] Financial Forecasts - EPS is forecasted at Rmb2.35 and Rmb2.74 for 2025-2026, indicating a CAGR of 16% [5] - EBITDA is projected at Rmb36.2 billion and Rmb40.4 billion for 2025-2026 [5] - H-shares are trading at 5.5x 2025e EV/EBITDA, with a target price set at HK$50.37, offering a 30% upside [5]

Financial Data and Key Metrics Changes - In Q1 2025, total sales reached $273.2 million, reflecting a 6% increase year-over-year, driven by strong performance in Sealing Technologies and Advanced Surface Technologies (AST) [11] - Adjusted EBITDA for the first quarter was $67.8 million, up over 16% compared to the prior year, with an adjusted EBITDA margin of 24.8%, expanding by 210 basis points year-over-year [12][19] - Adjusted diluted earnings per share increased by 21% to $1.9, supported by the factors driving adjusted EBITDA growth [13] Business Line Data and Key Metrics Changes - Sealing Technologies segment sales increased by 4.7% to $179.6 million, with adjusted segment EBITDA rising nearly 11% and a margin of 32.7% [13][14] - Advanced Surface Technologies saw a 9.1% increase in sales to nearly $94 million, with adjusted segment EBITDA up 18.5% and a margin of 21.9% [15][16] Market Data and Key Metrics Changes - The aerospace, general industrial, and food and pharma markets contributed to the growth in Sealing Technologies, while commercial vehicle OEM demand remained weak [6][14] - In the AST segment, double-digit growth was noted in Precision Cleaning Solutions and Optical Coatings and Filters, despite ongoing volatility in semiconductor capital equipment spending [8][15] Company Strategy and Development Direction - The company is focused on organic growth opportunities and capability expansions through acquisitions that meet strategic and financial criteria [7] - EnPro is positioned to leverage technological innovation and applied engineering expertise to gain market share, particularly in aerospace markets [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate economic uncertainties and emphasized the importance of agility and leadership development [5][10] - The guidance for 2025 remains unchanged, with expectations for sales growth in the low to mid-single-digit range and adjusted EBITDA between $262 million to $277 million [19][20] Other Important Information - The company amended its credit agreement to provide a revolving credit facility of up to $800 million, enhancing financial flexibility for strategic growth initiatives [17] - Free cash flow for Q1 was $11.6 million, with capital expenditures expected to be around $50 million for the year [18] Q&A Session Summary Question: Can you provide numbers regarding the minimal and manageable impact of tariffs? - Management indicated that most products are produced regionally, with minimal exposure to tariffs, particularly from imports [28][30] Question: Are there any end markets that are performing better or worse compared to 90 days ago? - Management feels equally positive about all markets, with commercial vehicle demand as expected and strong performance in aerospace and food and pharma [32][33] Question: What is the outlook for margin expansion in Sealing Technologies? - Margin expansion was primarily driven by favorable mix and strategic pricing initiatives, with strong demand in aftermarket and aerospace markets [56][58] Question: Any updates on the Arizona facility? - The facility is on track, with early revenue from testing and qualification expected to ramp up throughout the year [44][45] Question: Is M&A activity slowing down due to the current environment? - While M&A activity has slowed, the company remains focused on high-quality assets and is patient in its approach to acquisitions [50][51]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $275.2 million, an increase of 48.9% year over year, driven by increased clients and transactions [8][17] - Contribution profit was $87.6 million, up 26.3% year over year, with an adjusted EBITDA of $30 million, reflecting a 51.3% increase year over year [8][21] - Adjusted EBITDA margin reached a record 34.2%, with over 50% of year-over-year growth in contribution profit dropping to the bottom line [9][22] - The company ended Q1 with total cash and cash equivalents of $249.6 million, up from $209.4 million at the end of 2024, and generated a record free cash flow of $41.1 million [23][24] Business Line Data and Key Metrics Changes - The company signed clients across various industry verticals including utilities, government agencies, telecommunications, banking, insurance, and education, indicating a diverse client base [11][12] - The onboarding of large enterprise clients has contributed significantly to transaction growth, with a higher level of transactions processed reaching $173.2 million, up 28% year over year [17][18] Market Data and Key Metrics Changes - The company continues to serve essential sectors of the domestic economy, focusing on non-discretionary bills such as utilities and insurance, which are fundamental for households [5][6] - The average revenue per transaction increased to $1.59 from $1.37 in the prior year, attributed to the mix of large enterprise billers [17][18] Company Strategy and Development Direction - The company aims to maintain a compound annual growth rate (CAGR) of 20% for revenue and 20% to 30% for adjusted EBITDA, with a focus on leveraging operating efficiency [9][28] - The management emphasizes the importance of their technology platform and ecosystem, which reduces costs for clients while improving customer experience [7][32] - The company is exploring potential M&A opportunities but remains focused on organic growth, with no immediate need for acquisitions [25][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's performance despite macroeconomic challenges, citing strong sales momentum and a solid pipeline for future growth [5][31] - The management noted that they are not seeing any changes in sales cycles or implementation speeds, indicating resilience in their business model [44][45] - The company believes it is well-positioned for further growth, with a strong backlog and encouraging trends in consumer and business payment behaviors [29][31] Other Important Information - The company has a strong cash position, allowing for financial flexibility and the potential for strategic investments [25][51] - The management highlighted the importance of their diverse partner ecosystem, which complements their direct go-to-market strategy [12][102] Q&A Session Summary Question: Transaction growth trends and contributions from new vs. existing clients - Management indicated that both new customer implementations and same-store sales are growing, with new implementations currently contributing more significantly [37][38] Question: Dynamics behind gross revenue guidance - Management explained that the guidance reflects caution regarding large enterprise customers, as their growth patterns are still being assessed [39][41] Question: Changes in sales cycles or implementation pace due to macro uncertainty - Management reported no significant changes in sales cycles or implementation speeds, maintaining a strong pipeline [44][45] Question: M&A opportunities and criteria - Management stated that M&A is a secondary objective, with no immediate needs or specific criteria set for potential acquisitions [49][50] Question: Free cash flow conversion and expectations - Management emphasized that while free cash flow can fluctuate, they expect to generate decent cash annually after taxes [56][58] Question: Trends in demand across various verticals - Management noted strong performance across multiple verticals, with a proven platform that meets the needs of diverse clients [90][91] Question: Long-term operating margin expectations - Management refrained from providing specific long-term margin targets but indicated confidence in achieving good operating leverage [93][94]